ZURA Company Profile and Key Details

Zura Bio Limited (NASDAQ:ZURA) closed at $5.15 USD, gaining $0.04 (0.78%) from the previous close of $5.11. The stock is currently mid-range between its 52-week high and low $1.26 and $7.44. With a market capitalization of about $334.86 million, Zura Bio Limited is classified as a small-cap and shows lower-than-market volatility (beta ~-0.04). Key stats such as the average daily volume over the past year has been around 1.07 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Zura Bio Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sandeep C. Kulkarni, the company employs approximately 40 people and listed since March 21, 2023. Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases.

Short-term trend indicators are bearishly aligned (SMA20 8.72%, SMA50 21.66%, SMA200 114.89%). The stock’s 14-day RSI is 62.37 (firm momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.84% below its high and over 597.94% above its low. Average 10-day trading volume of 1.15 million shares is in line with the 3-month average of 1.09 million, indicating normal recent market interest.

Zura Bio Limited trades at a P/E ratio of -4.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.63 suggesting the stock is closer to book value. The P/FCF stands at -4.54, also below market averages.

Zura Bio Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.16. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of -3.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $2.00. The high target offers 249.51% upside. The low target suggests -61.17% downside. The mean target is $12.20. This offers 136.89% upside. Zura Bio Limited earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 29.41%. The prior quarter beat by 172.22%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in March 25, 2025.

Zura Bio Limited has 65.02 million shares outstanding. The public float is 37.88 million shares, elevated short interest at 0.72% of float. This equals 425.34 thousand shares. The short ratio is 1.15 days. Institutional investors hold 99.67% of the float. Insiders own 29.16%. AI Biotechnology LLC holds 6.55 million shares, Sidhu Someit has 2.09 million shares and Munshi Amit has 777.38 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.